<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197561</url>
  </required_header>
  <id_info>
    <org_study_id>HD43555</org_study_id>
    <nct_id>NCT00197561</nct_id>
  </id_info>
  <brief_title>Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection</brief_title>
  <official_title>Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the oral administration of daily selenium
      supplements to HIV-1 positive pregnant women: enhances immune status and reduces the HIV-1
      viral load at six months postpartum, reduces the risk of lower genital shedding of HIV-1
      infected cells at 36 weeks of gestation, and reduces the risk of mastitis at six weeks
      postpartum, compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are recruiting pregnant women who are infected with HIV and assign them to receive
      selenium or placebo. All women will be given standard prenatal care, including nevirapine for
      the prevention of mother-to-child transmission and prenatal multivitamin supplements. We will
      examine the effect of the selenium supplements on intermediate outcomes predictive of the
      risks of transmission of HIV and to disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD4 cell counts and viral load from baseline to six weeks and six months postpartum in HIV-1 positive women</measure>
    <time_frame>Enrollment (12-27 wks gestation) to 6 months postpartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of lower genital shedding of HIV-1 infected cells at 36 wks gestation</measure>
    <time_frame>At 36 wks gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of subclinical mastitis as defined by elevated sodium concentrations in breastmilk at 6 weeks postpartum</measure>
    <time_frame>6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal death, premature delivery, and low birth weight</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">915</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Selenium (200 ug as selenomethionine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taken orally once per day from randomization through delivery and through the first 6 months after delivery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery</description>
    <arm_group_label>Selenium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 Infected women between 12 and 27 weeks of gestation

        Exclusion Criteria:

          -  Women with clinical AIDS defined according to WHO Criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wafaie W. Fawzi, MD, DrPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Muhimibili University College of Health Scienes</name>
      <address>
        <city>Upanga</city>
        <state>Dar es Salaaam</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Kupka R, Mugusi F, Aboud S, Hertzmark E, Spiegelman D, Fawzi WW. Effect of selenium supplements on hemoglobin concentration and morbidity among HIV-1-infected Tanzanian women. Clin Infect Dis. 2009 May 15;48(10):1475-8. doi: 10.1086/598334.</citation>
    <PMID>19368503</PMID>
  </results_reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wafaie Fawzi</name_title>
    <organization>Harvard School of Public Health</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Selenium</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Women</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Tanzania</keyword>
  <keyword>Maternal and child health outcomes</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>Pregnancy Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

